Acute myeloid leukemia(AML) is a heterogeneous disease characterized by complex molecular and cytogenetic *** approaches to predict the prognosis of AML have increasingly attracted *** were 98 non-M3 AML cases and 48 ...
详细信息
Acute myeloid leukemia(AML) is a heterogeneous disease characterized by complex molecular and cytogenetic *** approaches to predict the prognosis of AML have increasingly attracted *** were 98 non-M3 AML cases and 48 healthy controls were enrolled in the current *** routine assays for cytogenetic and molecular genetic analyses were performed on the bone marrow samples of AML ***,metabolic profiling of these AML subjects were also performed on the serum samples by combining Ag nanoparticles-based surface-enhanced Raman spectroscopy(SERS) with proton nuclear magnetic resonance(NMR) *** most of the routine biochemical test showed no significant differences between the M0～M2 and M5 groups,the metabolic profiles were significantly different either between AML subtypes or between prognostic risk *** SERS bands were screened to serve as potential markers for AML *** results demonstrated that the classification models for M0～M2 and M5 shared two bands(i.e.,1328 and 741 cm-1),all came from nucleic acid ***,Metabolic profiles provided various differential metabolites responsible for different AML subtypes,and we found altered pathways mainly included energy metabolism like glycolysis,pyruvate metabolism,and metabolisms of nucleic acid bases as well as specific amino acid *** is concluded that integration of SERS and NMR provides the rational and could be reliable to reveal AML differentiation,and meanwhile lay the basis for experimental and clinical practice to monitor disease progression and prognostic evaluation.
目的探讨氟达拉滨联合环磷酰胺(FC)和氟达拉滨、环磷酰胺联合利妥昔单抗(FCR)方案治疗慢性淋巴细胞白血病(CLL)的临床疗效和安全性。方法以FCR方案为试验组,FC方案为对照组。通过计算机检索PubMed、Cochrane Library、Embase、中国知网、万方、维普数据库,并进一步对纳入文献的参考文献进行扩大检索。对符合纳入标准的随机对照研究(RCT)按Cochrane系统评价的方法,独立进行资料提取、质量评价并交叉核对后,采用StataMP 14.0软件进行Meta分析。结果共纳入7篇文献研究,包括1 985例患者。FCR方案较FC方案有着更好的完全缓解率和总体反应率,差异有统计学意义(RR=1.89,95% CI 1.64~2.18,P<0.01;RR=1.15,95% CI 1.10~1.21,P<0.01)。在患者Ⅲ~Ⅳ级不良反应方面,FCR方案较FC方案中性粒细胞减少更严重,差异有统计学意义(RR=1.25,95% CI 1.01~1.55,P=0.004)。结论FCR方案较FC方案在治疗CLL方面有着更好的临床疗效和预后,同时也伴有严重的Ⅲ~Ⅳ级中性粒细胞减少。
暂无评论